Skip to main content

Development Of A Temperature Sensitive Trivalent Bordetella Avium Vaccine

ID: 2016-021 Temperature sensitive mutants against three prominent Bortadella like isolates causing epidemics in turkey flocks.

ID: 2016-021
Principal Investigator: Marcus Jensen

A disease known as coryza has been effectively controlled in the past by a turkey nasal vaccine developed by our inventor in 1979. However, certain mutant strains have developed. These mutant strains can now be controlled this new trivalent vaccine. The vaccine is administered to poults through their drinking water.

The Development of a Temperature Sensative Trivalent B. Avium Vaccine has the potential to provide turkey producers with the means to protect their flocks against harmful B. avium infections without the use of antibiotics. Thus, producers can accommodate consumer taste and demand while protecting the health and subsequent meat yields of their turkey flocks.

About the Market:

Consumer demand for chicken, turkey, pork, and beef raised without the routine use of antibiotics is growing fast. In this niche market in 2012, sales were up 25 percent over the three prior years. The increase occurred despite an overall decline in U.S. per capita meat consumption across the four major categories (beef, pork, chicken and turkey) over those same years. This trend continues today. USDA certified organic meats—just one part of the market for meat raised without routine use of antibiotics—were the fastest growing segment of the $31 billion organic foods industry in 2011.4 In 2013, sales of organic meat, poultry, and fish were up 11 percent over the prior year to $675 million. Shown in the figure are recent trends in the U.S. ABF chicken market and can be taken to be reflective of the U.S. ABF turkey market.

For more information, contact Mike Alder (801-422-3049)

Links and Resources

  1. One Page Summary PDF
  2. BYU News Article
  3. Inventor Webpage - Richard Robison